OncoMatch/Clinical Trials/NCT05586074
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Is NCT05586074 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for leukemia, acute myeloid (aml).
Treatment: Clifutinib · LoDAC · Azacitidine · Decitabine · Ara-C±IDA · FLAG-IDA — A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared to salvage chemotherapy, and also to investigate the efficacy of Clifutinib as assessed by CR/CRh rate in these subjects.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Biomarker criteria
Required: FLT3 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: AML therapy — first-line
Subject is refractory to or relapsed after first-line AML therapy (with or without hematopoietic stem cell transplant )
Cannot have received: FLT3 inhibitor
Subject has received prior treatment with other FLT3 inhibitors
Cannot have received: AML therapy
Subject has AML that has relapsed after or is refractory to more than 1 line of therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify